Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2149-2154

  Rose, Warren E ^a   Knier, Ryan M ^a   Hutson, Paul R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Glycopeptides; hVISA; Pharmacokinetics; Resistance

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SIMULATION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CELL WALL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 77957227488     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq292     Document Type: Article

References (25)

1. Rybak MJ, Leonard SN, Rossi KL et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46: 2950-4.
2. Maor Y, Rahav G, Belausov N et al. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007; 45: 1511-4.
3. Garnier F, Chainier D, Walsh T et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006; 57: 146-9.
4. Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
5. Howden BP, Johnson PD, Ward PB et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 3039-47.
6. Maor Y, Hagin M, Belausov N et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
7. Cui L, Ma X, Sato K et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41: 5-14.
8. Cui L, Iwamoto A, Lian JQ et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 428-38.
9. Cui L, Murakami H, Kuwahara-Arai K et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44: 2276-85.
10. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187: 929-38.
11. Nelson JL, Rice KC, Slater SR et al. Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Antimicrob Agents Chemother 2007; 51: 616-22.
12. Bhateja P, Purnapatre K, Dube S et al. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains. Int J Antimicrob Agents 2006; 27: 201-11.
13. Rose WE, Leonard SN, Rossi KL et al. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2009; 53: 805-7.
14. Akins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000; 44: 1925-9.
15. Wootton M, Howe RA, Hillman R et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
16. Walsh TR, Howe RA, Wootton M et al. Detection of glycopeptide resistance in Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 357-8.
17. Del Nozal MJ, Bernal JL, Pampliega A et al. High-performance liquid chromatographic determination of vancomycin in rabbit serum, vitreous and aqueous humour after intravitreal injection of the drug. J Chromatogr A 1996; 727: 231-8.
18. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46: 1492-502.
19. Sieradzki K, Tomasz A. Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus. Antimicrob Agents Chemother 2006; 50:527-33.
20. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
21. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007; 30: 398-408.
22. Patel JB, Jevitt LA, Hageman J et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42: 1652-3.
23. Mwangi MM, Wu SW, Zhou Y et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104: 9451-6.
24. Lodise TP, Patel N, Lomaestro BM et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
25. Lodise TP, Lomaestro B, Graves J et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.